

4 April 2023

Dear Shareholder

THE HYDRATION PHARMACEUTICALS COMPANY LIMITED – UPCOMING ANNUAL GENERAL MEETING OF SHAREHOLDERS

The Hydration Pharmaceuticals Company Limited (ACN 620 385 677) (**ASX:HPC**) (**Hydralyte North America** or the **Company**) advises that the Company will hold its annual general meeting of its shareholders (**Shareholders**) at 11:00am (AEST) on Friday, 5 May 2023 (the **Meeting**).

The Meeting will be held as a hybrid meeting. Shareholders may attend in person at cdPlus Corporate Services, Level 42, Rialto South Tower 525 Collins Street, Melbourne Victoria 3000, or online via an online meeting platform.

The Company is not required to send hard copies of the Notice of Meeting (**Notice**) to Shareholders. The Notice is available under the 'ASX Announcements' section on the Company's website at <https://hydralyte.com/pages/investors> or under the Announcements section on the Company's ASX platform at <https://www2.asx.com.au/markets/trade-our-cash-market/announcements.hpc>


The Company strongly encourages all Shareholders to vote by proxy prior to the Meeting. Proxy forms for the Meeting should be lodged before 11:00am (AEST) on Wednesday, 3 May 2023. A copy of your personalised voting form is enclosed for convenience, or alternatively, you can submit your votes online via <https://investor.automic.com.au/#/loginsah> and follow the instructions on your Voting Form.

Shareholders who wish to attend and participate in the virtual Meeting can do so via the online meeting platform, where Shareholders will be able to watch, listen, ask questions and vote online. Details on how to access the virtual Meeting are provided in the Notice. Shareholders can also submit, and are encouraged to submit, any questions in advance of the Meeting by emailing questions to hydralytecossec@cdplus.com.au by no later than 11:00am (AEST) on Wednesday, 3 May 2023.

The Notice and the accompanying Explanatory Memorandum should be read in its entirety. The Explanatory Memorandum contains important information about the matters to be considered at the Meeting to assist Shareholders to determine how to vote on the resolutions set out in the Notice.

Should you wish to discuss any of the matters detailed in this letter, the Notice or the Explanatory Memorandum, please contact the Company Secretary on +61 3 9614 2444 or hydralytecossec@cdplus.com.au.

Yours faithfully



George Livery
Chair
The Hydration Pharmaceuticals Company Limited